Clinical Trials for Thyroid Cancer
1 Open Trial
| Trial Type | Protocol No. & Open Date | Summary |
|---|---|---|
| Therapeutic | COGADVL1121 06/13/2012 | ADVL1121 - A Phase II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (IND# 69896) in Children and Young Adults With Relapsed/Refractory Rhabdomyosarcoma, Wilms Tumor, Hepatocellular Carcinoma, and Papillary Thyroid Carcinoma |
You do not have JavaScript enabled. This site works better with JavaScript turned on.
